

June 17, 2020

Evan Ce Xu  
Chief Financial Officer  
Genetron Holdings Limited  
1-2/F, Building 11, Zone 1  
No.8 Life Science Parkway  
Changping District, Beijing, 102206  
People's Republic of China

Limited  
Registration Statement on Form F-1  
2020

Re: Genetron Holdings  
Amendment No. 2 to  
Filed on June 15,  
File No. 333-234805

Dear Mr. Xu:

We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our June 12, 2020 letter.

Amendment No. 2 to Form F-1  
Capitalization, page 76

1. We note the change in the Share Capital and Share Premium balances from pro forma to pro forma as adjusted appears to be inconsistent with the disclosure of the expected net proceeds of US\$146,100 million disclosed in Use of Proceeds on page 74. Please clarify or revise.

Evan Ce Xu  
Genetron Holdings Limited  
June 17, 2020  
Page 2

Dilution, page 78

2. We note that you provide the net tangible book value per ordinary share at March 31, 2020. In addition, please revise your disclosure to provide the net tangible book value at March 31, 2020.

3. Please tell us how you calculated the pro forma net tangible book value as adjusted of US\$195.28 million as it appears to be inconsistent with the net tangible book value at March 31, 2020 adjusted for the conversion of your outstanding preferred shares and the net proceeds received in the offering.

4. The number of outstanding shares of existing shareholders of 361,810,100 appears to be inconsistent with the number of shares of ordinary shares of 119,433,500

disclosed in

Note 15 of your March 31, 2020 financial statements on page F-90 and the  
220,332,100

shares from the conversion of the issued and outstanding preferred shares  
disclosed

above. Please clarify or revise.

Liquidity and Capital Resources, page 108

5. We note your response to prior comment 1. Please disclose the material  
terms of your

loan agreements, such as the interest rate and default interest.

Business, page 130

6. We note your response to prior comment 1. Please disclose the material  
terms of your

material agreements, such as the expiration term of the iKang and  
Innocare agreements.

You may contact Blaise Rhodes at 202-551-3774 or Angela Lumley at  
202-551-3398 if

you have questions regarding comments on the financial statements and related  
matters. Please

contact Ruairi Regan at 202-551-3269 at Brigitte Lippmann at 202-551-3713 with  
any other

questions.

Sincerely,

FirstName LastNameEvan Ce Xu

Division of

Corporation Finance  
Company NameGenetron Holdings Limited

Office of Real

Estate & Construction

June 17, 2020 Page 2

cc: Li He, Esq.

FirstName LastName